2019 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ - ICKSH 2019 (3¿ù 15ÀÏ) : 2019-03-15±³À°ÀÏÀÚ : 2019-03-15
±³À°Àå¼Ò : ±×·£µå¿öÄ¿ÈúÈ£ÅÚ ºñ½ºÅ¸È¦
±³À°ÁÖÁ¦ :
2019 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ - ICKSH 2019 (3¿ù 15ÀÏ)ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ±èÇìÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 9 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í Æç·Î¿ì, °£È£»ç, ¿¬±¸¿ø, Çлý, Àü°øÀÇ 50,000¿ø ºñȸ¿ø 200,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 09:00~09:30 Euro Blood Net : The rare anaemia disorders European epidemiological platform Maria del mar Manu(Spain)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 09:30~10:00 Clinical utility of high-throughput sequencing for the diagnosis of hereditary hemolytic anemia ±è¸í½Å(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 09:00~10:30 The molecular specrum of hemoglobinopathy : Thalassemia and Hb variants Cornelis Leonard harteveld(The Netherlands)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 10:45~11:15 Breakthroughs in the treatment of aplastic anemia Neal Sturt Young(USA)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 11:15~11:45 Breakthroughs in the treatement of DLBCL Bertrand Coiffer(France)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 11:45~12:45 Predictive role of geriatric assessment for early events in elderly AML fit for intensive chemotherapy; interim data of a prospective cohort study ¹Î±âÁØ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 12:45~13:40 A new paradigm shift in frontline treatment of hodgkin lymphoma Andrea Gallamini(France)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 13:50~15:05 Real world experience of carfilzomib, and dexamethasone versus pomalidomide-Based combination chemotherapy after a 2nd-Line therapy in RRMM ÀÌÁöÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 15:05~16:20 Highly Sensitive Detection of BCR-ABL in Clinical Samples by QXDx BCR-ABL %IS Digital Droplet PCR Á¤ÈñÁ¤(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 16:35~17:05 Genomics of Core-binding factor AML Nicolas Dupoyez(Frane)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 17:05~17:35 Precision medicine in AML in the era of novel agents Gail J. Roboz(USA)
±³À°½Ã°£ 03¿ù 15ÀÏ VISTA 2 17:35~18:05 Incorporation of molecular assessments in risk statification for myelodysplastic syndromes: Ready for prime time? Amer M Zeidan(USA)